Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol, 38, 286-90.Chen X, Cong Y, Pan L, et al. Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol. 2014;38(3): 286-290....
ER+ and HER2/neu-negative subtype Basal-like breast cancer Breast cancer diagnosis A diagnostic delay, or the time between when you first notice symptoms and when you are diagnosed with breast cancer, determines how quickly you’re treated. The longer it takes to get that diagnosis, the longer...
目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2−) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily practice. The objectives of this study were to inv...
[2] Erika P. Hamilton, Sara A. Hurvitz, Seock-Ah Im, et al., Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. JCO 42, 1025-1025(2024). DOI:10.1200/JCO.2024.42...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
several subtypes that account for 10-20% of cancer among women globally, being negative for three most important receptors (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)), with an early and high recurrence resulting in poor ...
Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat? Background Since the addition of trastuzumab to (neo)adjuvant chemotherapy, the prognosis of patients with stage II and III HER2-positive ...
Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients. ER+PR-HER2- tumor benefits less from endocrine therapy...
inflammatory carcinoma can be difficult to diagnose. Another highly aggressive form of the disease is triple negative breast cancer, in which tumour cells lack expression of ER, PR, and HER2 proteins. This makes treatment more difficult, since many agents for breast cancer specifically target one ...